Search results for "anticholinergic"

showing 10 items of 33 documents

A Predictive Model of the Prevalence of Delirium in Elderly Subjects Admitted to Nursing Homes.

2017

INTRODUCTION Delirium is common in geriatric patients admitted to nursing homes, with an incidence of 22-79% among long-term residents. AIM To establish a predictive model of the risk of delirium episodes in a sample of elderly people living in nursing homes. MATERIAL AND METHODS A retrospective, cross-sectional case-control study covering a period of 12 consecutive months (April 2014 - March 2015) was carried out. The included cases had suffered at least one episode of delirium during the study period. Sociodemographic and clinical variables as well as risk factors predisposing to or triggering episodes of delirium were recorded. RESULTS A total of 193 cases and 123 controls were recruited…

0301 basic medicineMaleEndocrinology Diabetes and MetabolismUrinary incontinenceCholinergic Antagonists0302 clinical medicinePatient AdmissionRisk FactorsOdds RatioPrevalenceImmunology and AllergyHomes for the AgedDepression (differential diagnoses)Aged 80 and overDepressionIncidence (epidemiology)Area under the curveAge FactorsArea Under CurveFemalemedicine.symptommedicine.medical_specialtymedicine.drug_classUrinary systemCommunicable Diseases03 medical and health sciencesInternal medicinemedicineAnticholinergicDementiaHumansIntensive care medicineGeriatric AssessmentRetrospective StudiesChi-Square Distributionbusiness.industryDeliriummedicine.diseaseNursing HomesAffect030104 developmental biologyCross-Sectional StudiesLogistic ModelsUrinary IncontinenceROC CurveSpainDeliriumDementiabusiness030217 neurology & neurosurgeryEndocrine, metabolicimmune disorders drug targets
researchProduct

Delirium Predisposing and Triggering Factors in Nursing Home Residents: A Cohort Trial-Nested Case-Control Study.

2019

Background Delirium is a common geriatric syndrome, with a prevalence of between 15-70% among older long-term care residents. It is associated with adverse outcomes, and its onset may prove imperceptible to health professionals. Few studies in institutionalized older people have analyzed the predictors of delirium. Objective The aim of the present study was to identify delirium predisposing and triggering factors, and develop a predictive model. Methods A cohort trial-nested case-control study covering a period of 12 consecutive months (April 2015 - March 2016) was carried out. Predisposing and triggering episodes of delirium were recorded. Results A total of 443 older persons were recruite…

0301 basic medicineMalemedicine.medical_specialtymedicine.drug_classPsychological interventionCholinergic AntagonistsCohort Studies03 medical and health sciences0302 clinical medicinemental disordersAnticholinergicmedicineDementiaHomes for the AgedHumansAgedAged 80 and overbusiness.industryGeneral NeuroscienceIncidence (epidemiology)Area under the curveDeliriumGeneral Medicinemedicine.diseasePrecipitating FactorsNursing HomesPsychiatry and Mental healthClinical Psychology030104 developmental biologyCase-Control StudiesCohortNested case-control studyEmergency medicineDeliriumAccidental FallsDementiaFemaleGeriatrics and Gerontologymedicine.symptombusiness030217 neurology & neurosurgeryJournal of Alzheimer's disease : JAD
researchProduct

A Stage-Based Approach to Therapy in Parkinson’s Disease

2019

Parkinson’s disease (PD) is a neurodegenerative disorder that features progressive, disabling motor symptoms, such as bradykinesia, rigidity, and resting tremor. Nevertheless, some non-motor symptoms, including depression, REM sleep behavior disorder, and olfactive impairment, are even earlier features of PD. At later stages, apathy, impulse control disorder, neuropsychiatric disturbances, and cognitive impairment can present, and they often become a heavy burden for both patients and caregivers. Indeed, PD increasingly compromises activities of daily life, even though a high variability in clinical presentation can be observed among people affected. Nowadays, symptomatic drugs and non-phar…

0301 basic medicinemedicine.medical_specialtyParkinson's diseaseImpulse control disorderlcsh:QR1-502ReviewDiseasel-dopaBiochemistryREM sleep behavior disorderMotor symptomslcsh:MicrobiologyAntiparkinson Agentsnon-pharmacological therapy03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationmedicineHumansdopamine-agonistsApathyanticholinergicsResting tremorMolecular Biologyamantadinebusiness.industryAmantadineParkinson Diseasemonoamine oxidase inhibitorsmotor symptomsmedicine.diseasenon-motor symptoms030104 developmental biologyacetylcholinesterase inhibitorsParkinson’s disease<span style="font-variant: small-caps">l</span>-dopaSettore MED/26 - Neurologiamedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugBiomolecules
researchProduct

Once-daily tiotropium Respimat® 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma

2015

SummaryIntroductionOnce-daily tiotropium Respimat® 5 μg is an efficacious add-on therapy to inhaled corticosteroids (ICS) with or without long-acting β2-agonists in patients with symptomatic asthma. The objective of this study was to investigate whether the dosing regimen of tiotropium (once- versus twice-daily), delivered via the Respimat® SoftMist™ inhaler, affected 24-h bronchodilator efficacy and safety versus placebo Respimat® in patients with asthma who were symptomatic despite medium-dose ICS therapy.MethodsA randomised, double-blind, placebo-controlled, crossover study with 4-week treatment periods of tiotropium 5 μg (once-daily, evening) and 2.5 μg (twice-daily, morning and evening…

AdultEstoniaMalePulmonary and Respiratory MedicineVital capacityRespimatEveningAdolescentmedicine.drug_classPlaceboDouble-Blind MethodRisk FactorsAnticholinergic drugForced Expiratory VolumeGermanyBronchodilatorAdministration InhalationmedicineHumansDosingDosing regimenTiotropium BromideAgedCzech RepublicAsthmaLong-acting bronchodilatorCross-Over StudiesDose-Response Relationship Drugbusiness.industryTiotropiumInhalerMiddle Agedmedicine.diseaseLatviaAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeBronchodilator efficacyAustriaAnesthesiaFemalebusinessRespiratory Medicine
researchProduct

Intoxication with a tropenol ester.

2012

BACKGROUND While the effects of medicinal products are investigated in depth before approval, often very little is known about the intermediates occurring during synthesis. The pharmacological properties of these intermediates can differ substantially from those of the end product. AIMS To describe a work accident involving intoxication with such an intermediate, tropenol ester. CASE REPORT A healthy 40-year-old chemical-technical operative erroneously used a scrubbing brush that had just been used to clear up tropenol ester, contaminating his work clothes. Presumably, contact was made with his skin when removing his work clothes later. Shortly thereafter, he developed signs of anticholiner…

AdultMaleMedical treatmentTertiary aminebusiness.industrymedicine.drug_classMydriasisPublic Health Environmental and Occupational HealthAntagonistEstersAnticholinergic agentsMuscarinic AntagonistsCholinergic AntagonistsSeizuresAnesthesiaOccupational ExposureToxicityMuscarinic acetylcholine receptorAnticholinergicMydriasisMedicineHumansAtaxiamedicine.symptombusinessOccupational medicine (Oxford, England)
researchProduct

A double-blind study comparing paroxetine and maprotiline in depressed outpatients.

1997

A double-blind multicenter randomized parallel group study comparing paroxetine and maprotiline was carried out in a total of 544 outpatients. Included were patients with varying degrees of severity of depressive symptoms who fulfilled modified RDC criteria for either Minor or Major Depression and showed a HAMD-17 score of > or = 13. No concomitant benzodiazepine treatment was allowed. Duration of treatment was 6 weeks, after an initial wash-out period. Doses were fixed during the first 3 weeks of treatment, patients receiving either 20 mg paroxetine or 100 mg maprotiline daily. An option for dose escalation was provided for insufficient responders after 3 weeks. The weekly assessments comp…

AdultMalemedicine.drug_classDouble-Blind MethodAnticholinergicAmbulatory CareMedicineHumansPharmacology (medical)Adverse effectMaprotilinePsychiatric Status Rating ScalesBenzodiazepineDepressive Disorderbusiness.industryGeneral MedicineParoxetinePsychiatry and Mental healthParoxetineMaprotilineConcomitantAnesthesiaAntidepressantAntidepressive Agents Second-GenerationFemalebusinessReuptake inhibitormedicine.drugPharmacopsychiatry
researchProduct

Urine tropenol ester levels in workers handling tiotropium bromide synthesis: implications for exposure prevention and biomonitoring

2019

Tropenol ester is a highly toxic anticholinergic substance and an intermediate used in industrial production of the bronchodilator tiotropium bromide. The aim of this study was to systematically test workers involved in its production for tropenol ester in urine to identify any exposure pathways and define additional preventive measures. Twelve workers performing tasks involving potential exposure to tropenol ester were repeatedly monitored at the end of each production cycle. Medical exams revealed no symptoms of acute poisoning with tropenol ester, but biological monitoring of urine showed 36 positive findings in 79 samples, with tropenol ester concentrations ranging between the detection…

AdultMalemedicine.drug_classProduction cycleAnticholinergic agentsUrinePharmacologyToxicologyCholinergic AntagonistsYoung Adult03 medical and health sciences0302 clinical medicineOccupational ExposureBronchodilatorBiomonitoringAnticholinergicmedicineHumans030212 general & internal medicineTiotropium Bromidebusiness.industryanaliza radnog mjesta; antikolinergici; međuproizvodi; prevencija; skopin esterPublic Health Environmental and Occupational Healthanticholinergic agents; intermediates; prevention; scopine ester; workplace analysisTiotropium bromide030210 environmental & occupational healthAcute toxicitybusinessBiological MonitoringEnvironmental Monitoringmedicine.drugArchives of Industrial Hygiene and Toxicology
researchProduct

A comparison study of moclobemide and doxepin in major depression with special reference to effects on sexual dysfunction

1993

A double-blind parallel-group comparison study of moclobemide versus doxepin in 237 patients with major depression confirmed that moclobemide was equal in efficacy and better tolerated than doxepin. It was less sedating and caused fewer anticholinergic adverse events as measured by the UKU side-effect rating scale. Unexpectedly, moclobemide therapy more often than doxepin resulted in increased sexual desire. An exploratory analysis of UKU-measured symptoms of impaired sexual function prior to commencement of the study revealed that moclobemide more often than doxepin led to an improvement of reduced libido and impaired erection, ejaculation and orgasm. This finding is compatible with the as…

AdultMalemedicine.medical_specialtyMonoamine Oxidase InhibitorsPersonality Inventorymedicine.drug_classLibidoMoclobemideSexual BehaviorDouble-Blind MethodMoclobemidemedicineAnticholinergicHumansPharmacology (medical)PsychiatryAdverse effectDepression (differential diagnoses)Depressive DisorderDose-Response Relationship DrugMiddle AgedDoxepinPsychiatry and Mental healthSexual dysfunctionAnesthesiaBenzamidesComparison studyFemaleDoxepinmedicine.symptomPsychologymedicine.drugInternational Clinical Psychopharmacology
researchProduct

β2 long-acting and anticholinergic drugs control TGF-β1-mediated neutrophilic inflammation in COPD

2012

AbstractWe quantified TGF-β1 and acetylcholine (ACh) concentrations in induced sputum supernatants (ISSs) from 18 healthy controls (HC), 22 healthy smokers (HS) and 21 COPDs. ISSs from HC, HS and COPD as well as rhTGF-β1 were also tested in neutrophil adhesion and in mAChR2, mAChR3 and ChAT expression experiments in human bronchial epithelial cells (16-HBE). Finally, we evaluated the effects of Olodaterol (a novel inhaled β2-adrenoceptor agonist) and Tiotropium Spiriva®, alone or in combination, on neutrophil adhesion and mAChRs and ChAT expression in stimulated 16-HBE. The results showed that 1) TGF-β1 and ACh concentrations are increased in ISSs from COPD in comparison to HC and HS, and T…

Agonistmedicine.medical_specialtymedicine.drug_classchemistry.chemical_compoundInternal medicineTGF-β1Anticholinergic drugMuscarinic acetylcholine receptormedicineCOPDReceptorMolecular BiologyBeta2 long actingCOPDChemistryOlodaterolTiotropium bromidemedicine.diseaserespiratory tract diseasesEndocrinologyMolecular MedicineNeutrophilic inflammationBronchoconstrictionmedicine.symptomAcetylcholinemedicine.drugBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
researchProduct

Antimuscarinic action of quinidine on the heart? A study in myocardial preparations from cat hearts

1984

Quinidine exerts anticholinergic effects which have been ascribed to atropine-like properties of the drug. We have examined the effects of acetylcholine on the force of contraction in isolated heart muscle preparations from cats and compared the inhibitory effects of atropine with those of quinidine. The effects of acetylcholine were antagonized competitively in the presence of atropine. The Schild-plot yielded a straight line; the slope was not significantly different from unity. In the presence of quinidine, the concentration-response curve of acetylcholine was shifted to the right as with atropine, however, the Schild-plot yielded a regression line which was not linear; the slope was sta…

AtropineMaleQuinidineInotropemedicine.medical_specialtymedicine.drug_classAction PotentialsIn Vitro TechniquesPharmacologyParasympatholyticInternal medicinemedicineAnticholinergicAnimalsPhosphodiesterase inhibitorPharmacologyPapaverineChemistryCell MembraneParasympatholyticsMyocardial ContractionQuinidineAcetylcholineElectrophysiologyAtropineEndocrinologyCatsFemaleAcetylcholineResearch Articlemedicine.drugBritish Journal of Pharmacology
researchProduct